ATTR-01 / Accession Therap - LARVOL DELTA

Accession Therapeutics doses first patient in Phase 1 clinical trial of TROCEPT-01 (ATTR-01), a novel cancer immunotherapy (PRNewswire) - "The ATTEST trial is an open label, dose-escalation and dose expansion study...designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TROCEPT-01 (ATTR-01) in patients with advanced carcinomas who have had at least one prior treatment course. The trial is being conducted at leading clinical sites across the UK. Additional trial sites will be activated as the study progresses, including in Spain where there is established expertise in the treatment of solid tumours."

Trial status • Solid Tumor

TROCEPT A tumor targeted precision immunovirotherapy enabling αvβ6 integrin positive tumor localized expression of an immune checkpoint inhibitor following intravenous delivery (SITC 2025) - "A phase 1 study, ATTEST, is evaluating safety and preliminary efficacy of intravenous delivery of ATTR-01 in patients with selected epithelial tumors expressing high levels of the target αvβ6 integrin, including non-small cell lung, urothelial, head and neck, pancreatic, endometrial and cholangiocarcinoma in multiple sites in UK.Ethics Approval Studies were carried out with appropriate ethical approval and Home Office licence references 19/WS/0164, 23/PR/0221 and PP1144128Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal"

Checkpoint inhibition • IO biomarker • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A phase 1 study of ATTR-01, a novel oncolytic adenovirus targeting αvβ6 integrin, which expresses an anti-PD-L1 antibody in tumors following IV delivery in patients with selected epithelial cancers (SITC 2025) - "Participants will be recruited having progressed after ≥ 1 line of standard of care therapy with six cancer types (non-small cell lung, urothelial, head and neck, pancreatic, endometrial, cholangiocarcinoma) that typically demonstrate a high frequency (≥ 75%) and high level of αvβ6 integrin expression. Recruitment will begin in Q4 2025."

Clinical • IO biomarker • Oncolytic virus • P1 data • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A phase I study of ATTR-01, a novel oncolytic adenovirus targeting αvβ6 integrin, which expresses the anti-PD-L1 antibody payload in tumour following intravenous delivery in patients with selected epithelial tumours (ESMO 2025) - "Participants will be recruited having progressed after ≥ 1 line of standard of care therapy with six cancer types (non-small cell lung, urothelial, head and neck, pancreatic, endometrial, cholangiocarcinoma) that typically demonstrate a high frequency (≥ 75%) and high level of αvβ6 integrin expression. Recruitment will begin in Q2 2025."

Clinical • IO biomarker • Oncolytic virus • P1 data • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

TROCEPT - A tumor-targeted precision immunovirotherapy enabling avb6 integrin-positive tumor-localized expression of an immune checkpoint inhibitor following intravenous delivery. (CICON 2025) - "No liver enzyme or inflammatory cytokine changes were observed with ATTR-01 even at the top dose equivalent to 3x1014viral particles. This data validates the tumour selectivity and safety profile of ATTR-01.A phase 1 study, ATTEST, is evaluating safety and preliminary efficacy of intravenous delivery of ATTR-01 in patients with selected epithelial tumours expressing high levels of the target αvβ6 integrin, including non-small cell lung, urothelial, head and neck, pancreatic, endometrial and cholangiocarcinoma in multiple sites in UK."

Checkpoint inhibition • IO biomarker • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

ATTEST: A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Accession Therapeutics Limited | Suspended ➔ Recruiting

Enrollment open • Solid Tumor

ATTEST: A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours (clinicaltrials.gov) - P1/2 | N=72 | Suspended | Sponsor: Accession Therapeutics Limited | Recruiting ➔ Suspended

Trial suspension • Solid Tumor

ATTEST: A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Accession Therapeutics Limited

New P1/2 trial • Solid Tumor